Movement Interpretation: Capricor surged on September 17 due to HOPE-3 data and DMD therapy

1. On September 17, the company announced that it will present HOPE-3 and open-label extension study data of Deramiocel, covering 24-month skeletal muscle and cardiac outcomes, at the World Muscle Society Congress to be held from September 29 to October 3. A total of 106 patients were randomized into the HOPE-3 study, with 82 reaching the 24-month observation point.
2. On September 17, the company disclosed that relevant delayed initiation analyses, natural history analyses, and 24-month data have been included in the recent major amendment to the Biologics License Application for Deramiocel. The FDA currently has set the PDUFA target action date for November 22. The company primarily focuses on research and development of cell and exosome therapies, with core indications for Duchenne Muscular Dystrophy.

(Disclaimer: This content is generated by AI technology based on publicly available information, for reference only and does not constitute investment advice.)